TABLE 1.
Baseline and postoperative patient characteristics by modified Aletti surgical complexity score (SCS) group
| Patient characteristics |
Low SCS N = 113 |
Intermediate SCS N = 70 |
High SCS N = 64 |
p | |||
|---|---|---|---|---|---|---|---|
| Number | % | Number | % | Number | % | ||
| Age in years | |||||||
| ≤65 years | 51 | 45.1 | 44 | 62.9 | 48 | 75 | 0.001 |
| >65 years | 62 | 54.9 | 26 | 37.1 | 16 | 25 | |
| ECOG performance status | |||||||
| 0 | 53 | 46.9 | 35 | 50 | 19 | 29.7 | 0.046 |
| 1 | 52 | 46 | 25 | 35.7 | 36 | 56.3 | |
| 2, 3, 4 | 8 | 7.1 | 10 | 14.3 | 9 | 14.1 | |
| Age‐adjusted Charlson comorbidity index | |||||||
| 0–2 | 62 | 54.9 | 49 | 70 | 46 | 71.9 | 0.033 |
| 3+ | 51 | 45.1 | 21 | 30 | 18 | 28.1 | |
| Body mass index (kg/m2) | |||||||
| ≤25 | 42 | 37.2 | 37 | 52.9 | 31 | 48.4 | 0.096 |
| >25 | 69 | 61.1 | 32 | 45.7 | 33 | 51.6 | |
| Timing of surgery | |||||||
| PDS | 10 | 8.8 | 26 | 37.1 | 39 | 60.9 | 0.001 |
| NACT | 103 | 91.2 | 44 | 62.9 | 25 | 39.1 | |
| Pre‐surgery haemoglobin | |||||||
| ≤109 g/L | 49 | 43.4 | 28 | 40.0 | 25 | 39.1 | 0.827 |
| >110 g/L | 64 | 56.6 | 42 | 60.0 | 39 | 60.9 | |
| Pre‐surgery albumin level | |||||||
| >35 g/L | 22 | 19.5 | 14 | 20 | 17 | 26.6 | 0.511 |
| >5 g/L | 91 | 80.5 | 56 | 80 | 47 | 73.4 | |
| Peritoneal Carcinomatosis Index | |||||||
| ≤6 | 65 | 57.5 | 18 | 25.7 | 2 | 3.1 | 0.001 |
| 7–12 | 21 | 18.6 | 29 | 41.4 | 6 | 9.4 | |
| >12 | 27 | 23.9 | 23 | 32.9 | 56 | 87.5 | |
| Level/distribution of disease | |||||||
| Level 1 (highest level of disease: pelvis) | 20 | 17.7 | 7 | 10 | 0 | 0 | 0.001 |
| Level 2 (highest level of disease: mid‐abdomen) | 45 | 39.8 | 19 | 27.1 | 5 | 7.8 | |
| Level 3 (highest level of disease: upper abdomen) | 48 | 42.5 | 44 | 62.9 | 59 | 92.2 | |
| Outcome of surgery: residual disease | |||||||
| None visible | 63 | 55.8 | 50 | 71.4 | 40 | 62.5 | 0.007 |
| ≤1 cm | 29 | 25.7 | 17 | 24.3 | 21 | 32.8 | |
| >1 cm | 21 | 18.6 | 3 | 4.3 | 3 | 4.7 | |
| Final FIGO stage | |||||||
| 3A/3B | 11 | 9.7 | 9 | 12.9 | 2 | 3.1 | 0.068 |
| 3C | 68 | 60.2 | 34 | 48.6 | 33 | 51.6 | |
| 4 | 31 | 27.4 | 26 | 37.1 | 29 | 45.3 | |
| Postoperative chemotherapy | |||||||
| Carboplatin (C) ± taxol (T) | 106 | 94 | 62 | 89 | 62 | 97 | 0.591 |
| C + T + bevacizumab | 20 | 18 | 15 | 21 | 8 | 13 | |
| Other | 5 | 4 | 5 | 7 | 2 | 3 | |
| No chemotherapy | 2 | 2 | 3 | 4 | 0 | 0 | |
| UK/India patient | |||||||
| UK (n = 195) | 108 | 95.6 | 53 | 75.7 | 34 | 53.1 | 0.001 |
| India (n = 52) | 5 | 4.4 | 17 | 24.3 | 30 | 46.9 | |
| Pre‐surgery EORTC QLQ‐C30 global score, mean (SD) | 65.1 (21.7) | 59.8 (19.9) | 58.1 (22.2) | 0.094 | |||
| Median, days | IQR | Median, days | IQR | Median, days | IQR | ||
| Length of hospital admission | 5 | 3 | 6 | 3 | 9 | 8 | 0.001 |
| Surgery to chemotherapy interval | 31 | 16 | 31 | 13 | 39 | 20 | 0.005 |
DDS, delayed debulking surgery; NACT, neoadjuvant chemotherapy; PDS, primary debulking surgery.